Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGO NYSEAMERICAN:GNS NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00$0.00▼$0.00N/A16.65N/AN/AGNSGenius Group$1.20-12.4%$0.74$0.21▼$2.37$105.37M10.984.59 million shs6.34 million shsPRTCPureTech Health$18.56+0.3%$17.96$13.30▼$25.00$445.93M1.114,894 shs661 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%GNSGenius Group0.00%-13.29%+150.92%+405.72%-37.56%PRTCPureTech Health0.00%+8.27%+4.59%+14.55%-13.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGNSGenius Group0.748 of 5 stars0.02.00.00.02.51.70.6PRTCPureTech Health1.9862 of 5 stars3.85.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/AGNSGenius Group 0.00N/AN/AN/APRTCPureTech Health 3.50Strong Buy$45.00142.44% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AGNSGenius Group$7.91M13.32N/AN/A$1.23 per share0.98PRTCPureTech Health$4.32M103.34$2.25 per share8.25$17.04 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AGNSGenius Group-$24.88MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/AGNSGenius GroupN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/AGNSGenius Group0.133.653.61PRTCPureTech HealthN/A9.339.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/AGNSGenius Group14.28%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%GNSGenius Group51.19%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionableGNSGenius Group48087.81 million42.86 millionNot OptionablePRTCPureTech Health10024.03 million22.75 millionNot OptionablePRTC, GNS, ONT, and ERGO HeadlinesRecent News About These CompaniesPureTech CEO Bharatt Chowrira steps downJuly 16, 2025 | thepharmaletter.comTPureTech Health CEO Bharatt Chowrira ResignsJuly 16, 2025 | marketwatch.comPureTech Announces Leadership TransitionJuly 16, 2025 | businesswire.comPureTech Health announces board chair Raju Kucherlapati steps downJuly 10, 2025 | investing.comPureTech Health plc (PRTC) Income Statement - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comPureTech Announces Board ChangeJuly 8, 2025 | businesswire.comPureTech Health (NASDAQ:PRTC) Trading 0.6% Higher - Still a Buy?July 1, 2025 | marketbeat.comWhy This Biotech Stock Just Doubled In A Single DayJune 26, 2025 | benzinga.comPureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF TrialMay 22, 2025 | businesswire.comPureTech’s deupirfenidone shows strong and durable efficacyMay 21, 2025 | thepharmaletter.comTPureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)May 9, 2025 | businesswire.comPureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International ConferenceMay 1, 2025 | finance.yahoo.comPureTech to Present Results from Phase 2b ELEVATE…May 1, 2025 | pharmiweb.comPPureTech Health plc (PRTC) Q4 2024 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comPureTech Announces Annual Results for Year Ended December 31, 2024April 30, 2025 | businesswire.comPureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | BenzingaApril 22, 2025 | benzinga.comLeerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)April 10, 2025 | markets.businessinsider.comPureTech Appoints Peel Hunt as Joint UK Corporate BrokerApril 9, 2025 | businesswire.comPureTech Appoints Peel Hunt as Joint UK Corporate BrokerApril 9, 2025 | businesswire.comPureTech Health Shares Fall After Nordic Capital Withdraws Offer PlanApril 8, 2025 | marketwatch.comNordic Capital steps away from potential PureTech Health buyoutApril 7, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the Start3 Catalysts Driving Plug Power’s Turnaround CaseBy Jeffrey Neal Johnson | July 18, 2025View 3 Catalysts Driving Plug Power’s Turnaround CaseDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthTop 5 Stocks for July: Momentum-Driven Picks to Watch NowBy Thomas Hughes | June 30, 2025View Top 5 Stocks for July: Momentum-Driven Picks to Watch NowNVIDIA’s Stock Price Hits New Highs: This Is What’s NextBy Thomas Hughes | June 26, 2025View NVIDIA’s Stock Price Hits New Highs: This Is What’s NextPRTC, GNS, ONT, and ERGO Company DescriptionsEntia Biosciences OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.Genius Group NYSEAMERICAN:GNS$1.20 -0.17 (-12.41%) Closing price 04:10 PM EasternExtended Trading$1.27 +0.07 (+5.75%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.PureTech Health NASDAQ:PRTC$18.56 +0.06 (+0.33%) Closing price 03:58 PM EasternExtended Trading$18.56 0.00 (-0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
